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levels to ensure no
(spontaneous) bleeding
in patients with an RBD
are inaccurate.
Patients with hereditary rare bleeding disorders (RBDs) present with diverse hemorrhagic
symptoms. Correlation between factor activity levels and clinical bleeding severity is poor for
most RBDs. Threshold factor activity levels have been previously described in relation to
bleeding severity but have not yet been validated. The Rare Bleeding Disorders in the
Netherlands (RBiN) study is a nationwide cross-sectional study of patients registered in all 6
Dutch Haemophilia Treatment Centers with a known RBD and who are age 1 to 99 years.
Bleeding scores were determined, and laboratory and clinical data were extracted from
patient files. In all, 263 patients were included, of whom 202 (77%) attended the scheduled
study visit. The median International Society of Thrombosis and Haemostasis (ISTH)
bleeding assessment tool (BAT) score was 9. Correlations between baseline factor activity
levels and ISTH BAT scores were strong for deficiencies in factor II (FII) (r 5 –0.792) and FX
(r 5 –0.838) and were moderate for deficiencies of fibrinogen (r 5 –0.683), FV (r 5 –0.623),
FVII (r 5 –0.516), FXIII (r 5 –0.516), and a2-antiplasmin (r 5 –0.594). There was no
correlation for FXI deficiency (r 5 –0.218). The RBD BAT identified more women (94% vs
83%) and children (100% vs 71%) with an RBD than the ISTH BAT did. Importantly, 48% of
patients had more severe bleeding than predicted for their baseline factor activity level. In
addition, 34% of patients were predicted to be asymptomatic, but they actually had grade 2
(31%) or 3 (3%) bleeding. Bleeding severity in patients with RBDs is more pronounced than
previously anticipated. The previously determined threshold factor activity levels to ensure
no (spontaneous) bleeding in patients with an RBD are inaccurate. This trial was registered
at www.clinicaltrials.gov as #NCT03347591.
Introduction
Rare bleeding disorders (RBDs) refer to hereditary deficiencies of fibrinogen, prothrombin (factor II
[FII]), FV, FVII, FVIII, FX, FXI, and FXIII as well as disorders of fibrinolysis. RBDs are generally
inherited as autosomal recessive disorders, except for dysfibrinogenemia and some cases of
FXI deficiency, which can be autosomal dominant. The prevalence of RBDs for homozygosity or
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compound heterozygosity varies from 1:500 000 to 1:2 000000.1
They are significantly more prevalent in population groups with
a high rate of consanguinity.1,2
The clinical presentation of RBDs is diverse, ranging from asymptom-
atic to severe spontaneous bleeding.3 The reported correlation
between the factor activity level and degree of bleeding varies
from strong and predictable (for deficiencies of fibrinogen,
FV1FVIII, FX, and FXIII) to no correlation for FXI deficiency as
reported in a multicenter cohort study (EN-RBD) among 489
patients.4 Overall, life-threatening bleeding episodes such as
cerebral bleeding and spontaneous hemorrhages in muscles
and joints seem to occur less frequently when compared with
hemophilia.2 However, the large variability between the in-
dividual RBDs makes it impossible to consider these disorders
only as a group.
Hemorrhagic disorders of fibrinolysis mainly consist of plasmino-
gen activator inhibitor type 1 (PAI-1) deficiency and a2-antiplasmin
(a2-AP) deficiency. The bleeding phenotype of patients with
fibrinolytic disorders is characterized by delayed bleeding after
trauma, surgery, and dental procedures.5 Bleeding in areas of
high fibrinolytic activity is also common, such as menorrhagia
and epistaxis.5 Another category of RBDs is FV Amsterdam. This
bleeding disorder is caused by a pathogenic gain-of-function variant
in the FV gene leading to an aberrant FV that binds tissue factor
pathway inhibitor (TFPI), prolonging the half-life and concentration
of TFPI, which results in severely reduced thrombin generation and
a bleeding tendency.6
Peyvandi et al4 described the minimal factor levels needed to
remain asymptomatic for RBDs, showing a large variety between
different coagulation factor deficiencies. Although heterozygous
patients are usually not considered to have a bleeding disorder,
factor activity levels that are needed to remain symptomatic vary
from 12 IU/dL for FV deficiency up to 56 IU/dL for FX deficiency.
These threshold levels are now often used in clinical practice;
however, they have not been validated in a separate patient
population.7
Bleeding assessment tools (BATs) have been used since 1982 for
the quantification of a bleeding tendency.8 Since then, several BATs
were developed for the assessment and quantification of bleeding
symptoms and diagnosis of bleeding disorders, including the
International Society of Thrombosis and Haemostasis (ISTH) BAT
in 2010.9-11 However, these BATs originally focused on patients
with von Willebrand disease (VWD). The ISTH BAT score has also
been validated in carriers of hemophilia, but few RBD patients have
been evaluated with these tools.12 In addition, BATs are known to
be of limited diagnostic value for patients with mild bleeding
disorders.13 In 2016, Palla et al14 published a novel BAT score for
patients with RBDs. The most important differences between the
ISTH BAT and the RBD BAT are (1) the RBD BAT has separated
the individual surgical items as tonsillectomy, minor surgery, and
major surgery instead of categorizing these as one item, (2) the
RBD BAT includes subtraction points in case there is no bleeding
after hemostatic challenges, and (3) the calculation of the score in
the RBD BAT corrects for sex and age and uses subtraction points
for specific hemostatic items. The RBD BAT score is a potentially
interesting diagnostic tool, but it has not yet been validated in
a separate RBD patient cohort.
Given the low prevalence of RBDs, systemically collected data
on these disorders are scarce.15 Over the past few years, several
registries in Europe and the United States have been developed
for patients with an RBD.16,17 However, data derived from
registries is still limited and is mostly absent for disorders of
fibrinolysis.
The aims of this study are to describe the Dutch RBD patient
population for the first time and to determine the usability of the
ISTH BAT and RBD BAT for this patient population. In addition,
we aim to validate the previously determined threshold factor
activity levels. Because the Dutch patient population was not
included in the EN-RBD study, this study can be used to validate
the results from the EN-RBD study in a separate RBD cohort.4,14
Materials and methods
Patient recruitment
A nationwide cross-sectional study was conducted among patients
with a hereditary RBD in The Netherlands: the Rare Bleeding
Disorders in the Netherlands (RBiN) study. All known patients with
an RBD in a Dutch hemophilia treatment center (HTC), including
those with fibrinolytic disorders, were invited to participate in this
study. Patients were recruited from all 6 Dutch HTCs: Expertise
Center for Hemophilia and Related Disorders (Leiden University
Medical Centre and HAGA Hospital, The Hague), Haemophilia
Treatment Center Nijmegen-Eindhoven-Maastricht (HTC NEM:
Radboud University Medical Centre, Maxima Medical Centre,
and Maastricht University Medical Center), Amsterdam Univer-
sity Medical Centers, University Medical Centre Groningen, van
Creveldkliniek (University Medical Centre Utrecht), and Erasmus
Medical Centre Rotterdam. Patients were included from October
2017 to November 2019. This study was approved by the Medical
Ethical Committee of Arnhem-Nijmegen. All patients (and/or
parents in the case of minors) provided written informed consent
in accordance with the Declaration of Helsinki.
Patient inclusion
This study included patients age 1 year or older. Patients with
a congenital coagulation factor deficiency were invited to partici-
pate if the specific coagulation factor activity level was below the
lower limit of normal, or if there was a proven pathogenic
heterozygous, compound heterozygous, or homozygous variant in
the gene encoding for an RBD factor deficiency. Patients were
diagnosed because of a bleeding tendency, family investigation, or
abnormal laboratory values upon screening (eg, before surgery).
HTC NEM is the only Dutch HTC that tests for PAI-1 deficiency
and hyperfibrinolysis. To avoid overdiagnosis and false-positive
results, laboratory tests for diagnosing a PAI-1 deficiency or
hyperfibrinolysis are performed only in case of an ISTH BAT score
$10, a positive family history of a fibrinolysis disorder, or in patients
with a typical fibrinolytic bleeding pattern (ie, delayed bleeding after
interventions and/or co-occurrence with obstetric failure).5,18
Patients with a PAI-1 deficiency were eligible for inclusion if the
PAI-1 activity level was below the detection limit and the PAI-1
antigen level was below the lower limit of normal (reference range,
3.4-39 ng/mL). Patients with hyperfibrinolysis were eligible if the
euglobulin clot lysis time ratio before and after application of
a tourniquet was $5.8 (reference range, 1.2-5.7, locally validated
assay).
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Assessment methods
Participating patients were asked to come to their HTC for a study
visit, during which the ISTH BAT and RBD BAT were conducted
and blood was drawn for laboratory testing.10,14 The number of
patients identified by the ISTH BAT and RBD BAT for the individual
coagulation factor deficiency was calculated by dividing the number
of patients with a positive score on the specific BAT by the number
of included patients for the total group and for children, women, and
men separately. The cutoff value for a positive or abnormal ISTH
BAT score was $4 in adult men, $6 in adult women, and $3 in
children.10,19 The cutoff value for a positive or abnormal RBD BAT
was$1.5 for men, women, and children.14 All participating patients
were interviewed about their clinical symptoms by 1 investigator
(J.L.S.) to conduct the BATs and to avoid inconsistencies. Patients
were divided into clinical bleeding severity categories (asymptom-
atic and grade 1, 2, or 3 bleeding) based on previous research on
RBD patients by Peyvandi et al4 in the EN-RBD study. This bleeding
severity scale uses the most severe bleeding a patient has ever
had. Category I refers to provoked bleeding episodes, category II
refers to spontaneous minor bleeding episodes (eg, bruising), and
category III refers to spontaneous major bleeding episodes (eg,
cerebral bleeds or hemarthrosis). To determine whether the
threshold levels to remain asymptomatic or free from grade 1, 2, or 3
bleeding are correct and may be used in clinical practice, patients
were classified as “correct” if they had no more severe bleeding
than expected considering their baseline factor activity level. If they
experienced more severe bleeding than predicted, they were
classified as “incorrect.” Data regarding the patients’ medical
history, baseline factor activity levels, treatment plan, and use of
other medications were extracted from electronic patient files.
Factor measurements were performed locally using 1-stage clotting
assay. In addition, participants were asked to complete an extensive
self-administered questionnaire that contained questions on their
bleeding disorder, quality of life, and social aspects. The results of
laboratory measurements in the central laboratory and the results of
the questionnaires will be analyzed separately.
Statistical analysis
Statistical analysis was performed using IBM SPSS Statistics 25.
Values are reported as medians with interquartile range (IQR).
Pearson’s correlation was used to correlate the ISTH BAT scores
with the RBD BAT scores and to correlate the ISTH BAT with
baseline factor activity levels. The strength of the correlations was
described by using the following classification: no correlation (0-
0.29), weak correlation (0.30-0.59), moderate correlation (0.50-
0.69), strong correlation (0.70-0.89), or very strong correlation
(0.90-1.0). McNemar’s test was used to compare the percentage of
patients identified by the ISTH BAT and the RBD BAT. A 2-sided
P , .05 was considered statistically significant.
Results
Patients
A total of 263 patients were included from October 2017 to
November 2019. Patient characteristics are provided in Table 1.
The median age at time of inclusion was 38.5 years (range, 1-87
years). Overall, 49% of included patients were adult women, 29%
were adult men, and 22% were children between age 1 and
18 years. Bleeding scores were available for 202 patients (77%).
The genotype was known in 26% of patients. All patients with factor
activity levels in the normal range had genetically confirmed
heterozygous pathogenic variants. Disorders of fibrinolysis were
relatively common, accounting for 21% of included patients. Eight
percent of patients were receiving prophylactic treatment, mainly
those with an FXIII deficiency or fibrinogen deficiency.
ISTH BAT bleeding scores
The overall median ISTH BAT score for the total group (n 5 202)
was 9 (IQR, 5-15). The median ISTH BAT score for adult female
patients was 11 (IQR, 6.5-15.5), and for pediatric patients, the
median score was 5 (IQR, 1-7). The individual ISTH BAT scores per
RBD are shown in Figure 1. There were large differences in the BAT
scores for each RBD. The highest median scores were seen in
patients with FV and FXIII deficiencies. Because scores were
available for only 2 patients with FV Amsterdam (16 and 19), they
are not shown in Figure 1. The presence of specific bleeding
symptoms in the ISTH BAT score per RBD are shown in Figure 2.
The number of patients with each symptom for the separate RBDs
is shown in supplemental Table 1. A symptom was scored as
present if the patient had a score of 1 or more on the ISTH BAT for
this item. Overall, the most common symptom was menorrhagia,
occurring in 77% of all included women age 14 years or older (n 5
119). All female patients with PAI-1 deficiency (n 5 12), hyper-
fibrinolysis (n 5 13), FXIII deficiency (n 5 2), or combined FV1VIII
deficiency (n 5 1) had menorrhagia. Other prevalent symptoms
were bleeding after surgery (76%), bleeding after tooth extractions
(65%), and postpartum hemorrhage (51%). The least common
symptoms were gastrointestinal bleeding (7%) and cerebral
bleeding (7%), the latter mainly occurring in patients with either
an FXIII deficiency (42%) or an FII deficiency (15%). Muscle
hematomas and hemarthrosis were also seen less often, except in
patients with an FXIII deficiency (58% and 50%, respectively).
Correlation between baseline coagulation factor
activity level and ISTH BAT score
Figure 3 shows the correlation between baseline coagulation factor
activity levels and the ISTH BAT score for each RBD. A strong
correlation between baseline coagulation factor activity level and
the ISTH BAT score was found for FII deficiency (r 5 –0.792; P 5
.001) and FX deficiency (r 5 –0.838; P 5 .162). A moderate
correlation was found for fibrinogen deficiency (r5 –0.583; P5 .001),
FV deficiency (r5 –0.697;P, .001), FVII deficiency (r5 –0.515;P,
.01), FXIII deficiency (r 5 –0.516; P 5 .086), and a2-AP deficiency
(r5 –0.592; P5 .01). There was no correlation for FXI deficiency (r5
–0.218; P 5 .238). PAI-1 deficiency and hyperfibrinolysis were not
quantifiable, so correlations could not be made for these disorders.
RBD BAT bleeding scores
The median RBD BAT score for the total group (n5 202) was 3.36
(IQR, 2.00-4.895), for adult female patients, 3.98 (IQR, 2.60-
5.265), and for pediatric patients, 3.30 (IQR, 2.79-4.10). The
individual RBD BAT scores per RBD are shown in supplemental
Figure 1. Figure 4A shows the correlation between the ISTH BAT
and RBD BAT scores. There was a correlation of 0.692 between
the 2 BATs (P , .001). The sensitivities for both bleeding scores
are shown in Figure 4B for the entire RBD group and separately for
children, women, and men. No difference could be found between
the RBD BAT vs the ISTH BAT (84% vs 80%; P5 .291). However,
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the RBD BAT was able to identify more women (94% vs 83%; P,
.01) and children (100% vs 71%; P, .01), whereas the ISTH BAT
identified more men (79% vs 57%; P , .01). The correlations
between baseline coagulation factor activity levels and the RBD
BAT were less pronounced than the correlations with the ISTH BAT
(supplemental Figure 2).
Bleeding severity grade and validation of threshold
factor activity levels
The distribution of bleeding severity per RBD is shown in Figure 5A.
In total, 16 patients (8%) were classified as asymptomatic. Grades
1, 2, and 3 bleeding were noted in 26 (13%), 122 (60%), and 38
patients (19%), respectively. Patients with FXIII deficiency had the
highest proportion of grade 3 bleeding (75%). Therewas a correlation
between the ISTH BAT and the bleeding severity grade, but there
was a wide spread in all of the bleeding categories except for the
asymptomatic patients (supplemental Figure 3). Figure 5B shows the
predicted bleeding grade of a patient calculated from his or her
individual factor activity level results, using previously determined
threshold levels per RBD.4 Overall, 48% of the patients had more
severe bleeding than predicted, based on their baseline factor activity
level. Over the whole group, 34% of patients were predicted to be
asymptomatic, but they actually had grade 2 (31%) or grade 3 (3%)
bleeding (not shown in Figure 5B). The greatest discrepancies were
observed for FV deficiency (57% incorrect), FVII deficiency (57%
incorrect), and FXI deficiency (59% incorrect).
Discussion
The RBiN study is the first study in which clinical data for Dutch
RBD patients are described. In all, the study population had
263 patients with a wide variety of baseline factor activity levels
and included both homozygous and heterozygous patients.
The bleeding severity revealed that the Dutch RBD population
showed a more severe bleeding pattern than the previously
































Figure 1. ISTH BAT scores of patients included in the
RBiN study. Black horizontal lines are medians.
Table 1. Baseline characteristics of the RBiN study population









Fibrinogen 41 (16) 22 (54) 11 (27) 8 (20) 38 (4-87) 700 mg/L (0-3180 mg/L) 5 (13) 21 (51)
FII 16 (6) 7 (44) 6 (38) 3 (19) 37 (10-77) 53% (0%-66%) 0 (0) 5 (31)
FV 25 (10) 11 (44) 8 (32) 6 (24) 36 (2-73) 35% (0%-60%) 1 (4) 4 (16)
FV Amsterdam 2 (1) 1 (50) 1 (50) 0 47.5 (31-64) 283% (271%-295%) 0 (0) 2 (100)
FV 1 FVIII 6 (2) 1 (17) 1 (17) 4 (67) 11 (1-35) 10% (2%-24%) 0 (0) 5 (83)
FVII 57 (22) 21 (37) 19 (33) 17 (30) 32 (2-82) 30% (0%-61%) 2 (4) 6 (11)
FX 8 (3) 5 (63) 1 (13) 2 (25) 29 (11-58) 33% (0%-55%) 1 (14) 2 (25)
FXI 43 (16) 22 (51) 11 (26) 10 (23) 41 (2-84) 35% (0%-58%) 0 (0) 4 (9)
FXIII 14 (5) 2 (14) 8 (57) 4 (29) 31.5 (5-60) 0% (0%-82%) 12 (86) 10 (71)
a2-AP 23 (9) 13 (57) 6 (26) 4 (17) 50 (6-76) 61% (0%-82%) 0 (0) 5 (21)
PAI-1 14 (5) 14 (100) 0 (0) 0 (0) 45 (20-60) 2.5 ng/mL (1.5-3.2 ng/mL) 0 (0) 0 (0)
Hyperfibrinolysis 14 (5) 12 (86) 2 (14) 0 (0) 49.5 (22-75) 8.6% (5.8%-12.7%) 0 (0) 0 (0)
Total 263 131 (50) 74 (28) 58 (22) 38.5 (1-87) NA 21 (8) 69 (26)
All data are n (%), unless otherwise stated. The columns for women and men show the number of patients aged 18 years or older, and the column for children shows patients younger
than 18 years old. For patients with FV Amsterdam, the reported value in the column for coagulation factor activity level is the TFPI level. For patients with hyperfibrinolysis, the reported value
in the column for coagulation factor level is the euglobulin clot lysis time ratio.
NA, not applicable.
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these RBiN patients often showed more severe bleeding than
was predicted for their baseline factor activity levels.
There was considerable heterogeneity in the bleeding phenotype
between different RBDs. This can be explained by the specific
bleeding phenotype of the RBD as well as the heterogeneous
population included in this study, which ranged from young
children to adults and from severe homozygous deficiencies to
mild heterozygous deficiencies. The large variety in clinical
phenotype within 1 RBD can be explained by the poor correlation
between baseline factor activity levels and bleeding phenotype.
For clinical practice, it remains important to always consider
the specific disorder of an individual patient. In general, the
ISTH BAT score of patients with an RBD was mainly dom-
inated by the following types of bleeding: bleeding after surgery,
after tooth extractions, after labor, and with menorrhagia. This is
often described as a relatively mild bleeding phenotype when
compared with hemophilia.2 Because clinical studies of hered-
itary bleeding disorders historically have focused on patients
with hemophilia, knowledge of female-specific bleeding is less
developed and may be underestimated. The high occurrence of
menorrhagia (77% of the female patients age older than
14 years) found in this study is similar to that in women with
VWD (73%) but higher than in carriers of hemophilia A (50%-
64%).12,21-23 Fifty-one percent of women in this study who
underwent labor had a postpartum hemorrhage (PPH). As shown
in Figure 2, PPH was especially common in patients with FXI
deficiency (70%; n 5 10), hyperfibrinolysis (70%; n 5 8), FVII
deficiency (63%; n5 8), and FV1FVIII deficiency (100%; n5 1).
None of the women with FXIII deficiency in this study had
experienced labor, so the prevalence of PPH could not be
calculated for this RBD. In women with VWD and carriers of
hemophilia, deliveries are complicated with PPH in 34% of
patients.24 More recently, slightly lower prevalences of PPH in
carriers of hemophilia have been reported (24%-30%).12,23
However, the results observed in this study are difficult to
interpret, because PPH was defined by the specific ISTH BAT
item, not by actual blood loss indicated in the electronic medical
record because these data were not available. Nevertheless, the
number of women scoring on this individual item is high, and
alertness on this topic is warranted.
The highest median ISTH BAT scores were found in patients with
FV deficiency (16), FXIII deficiency (15), PAI-1 deficiency (12), and
hyperfibrinolysis (12). Although it was expected for patients with
FXIII deficiency, their ISTH BAT scores may be underestimated
because 86% of patients with FXIII deficiency were receiving
prophylaxis.25 The high number of patients with FXIII deficiency who
experienced grade 3 bleeding can be explained by the fact that
most of these patients had a baseline factor activity level of 0. The
higher BAT scores in FV deficiency, known to be a mild bleeding
disorder, might be explained by the relatively low baseline factor
activity levels of the patients included in this study (Table 1).4 The
absence of a specific FV concentration to ensure prophylactic
treatment for these patients may further increase their BAT scores.
In addition, platelet FV levels were not available, so possibly patients
in this study had relatively low FV in their platelets as well.26 The mild
bleeding phenotype of FV deficiency is thought to be (partly)
caused by the low TFPI levels in these patients because TFPI binds
to FV.27 The hypothesis regarding the influence of TFPI levels on the
bleeding tendency is reinforced by the 2 patients in this study with
FV Amsterdam. With normal FV activity levels, they had very high
TFPI levels, resulting in ISTH BAT scores of 16 and 19. Possibly,
patients with FV deficiency in this study had relatively normal levels
or activity of TFPI, which would cause the higher bleeding tendency.
TFPI levels will be measured in the specific RBiN population (results
are outside the scope of this study). The high ISTH BAT scores in
patients with a PAI-1 deficiency and hyperfibrinolysis are possibly
an overestimation because of an inclusion bias; people with low
ISTHBAT scores andwithout another specific indication of a fibrinolytic
disorder did not undergo laboratory testing for these disorders. The
relatively high number of patients with a fibrinolysis disorder (23 with
a2-AP deficiency, 14 with a PAI-1 deficiency, and 14 with hyper-
fibrinolysis) and their high median ISTH BAT scores (7, 12, and 12,
respectively) illustrate the importance of performing additional
assays for fibrinolysis to diagnose these disorders. In addition, it is
noteworthy that all patients with PAI-1 deficiency or hyper-
fibrinolysis and the majority of patients with a2-AP deficiency had
at least grade 2 bleeding, meaning they experienced spontane-
ous bleeding and not only after interventions.
For all RBDs, the absence of a good correlation between coagulation



































































































Figure 2. Percentage of patients with different types
of bleeding symptoms. A symptom was scored as
being present if the patient had an ISTH BAT score on
that item of $1. *Patients who underwent a tooth extrac-
tion or surgery; **adult female patients; ***female patients
who underwent labor.
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are other essential variables contributing to the clinical bleeding
phenotype. In previous studies, a strong correlation between
coagulation factor activity level and clinical phenotype was found
for deficiencies of fibrinogen, FV1FVIII, FX, and FXIII.4 In this
study, the strongest correlations were found in patients with FII
or FX deficiencies. Only a small number of patients with an FX
deficiency were included in the RBiN study, which may explain










































































































































Figure 3. Correlation between baseline factor activity
levels and ISTH BAT scores with linear regression
lines. Panels show deficiencies in fibrinogen (A), FII (B), FV
(C), FVII (D), FX (E), FXI (F), FXIII (G), and a2-AP (H).
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activity level and clinical phenotype. The fact that only a moderate
correlation was found for fibrinogen deficiency in this study
suggests that the initial correlation found for this deficiency may
not be as strong as previously reported. The lack of an association
for FXI deficiency is consistent with the results from the study by
Peyvandi et al.4 Most likely, the balance of all coagulant and
anticoagulant factors will determine the bleeding severity. This
study is the first to describe a correlation between a2-AP and
bleeding severity and to show a moderate correlation. Global
hemostasis assays such as thrombin generation, could contribute
to the determination of an individualized bleeding phenotype. This
is an interesting topic for further research.
The patients in this study had a more severe bleeding phenotype
than patients in previous European studies.4,20 The patient population
in this study possibly had more severe factor deficiencies compared
with patients in those studies. Another explanation might be that the
methodologies of the studies were different: all of the patients in the
RBiN study were interviewed by the investigator, but the EN-RBD
study used electronical medical records to assess bleeding severity.
The previously determined factor activity levels to remain free from
different bleeding severity grades were incorrect in 48% of the patients
included in this study. This can be partly explained by the higher number
of patients in this study who suffered from grade 2 or 3 bleeding
compared with the EN-RBD study, which determined the threshold
levels.4 The only RBD with a good prediction of bleeding severity in this
studywas FXIII deficiency, with only 8%of patients having bleedingmore
severe than what was predicted. However, because patients with FXIII
deficiency in this study almost exclusively had very low factor activity
levels, more data are necessary on heterozygous patients to determine
whether the threshold levels are accurate. Overall, these results highlight
the importance of obtaining a complete overview of an individual
patients’ coagulation status. Given the fact that for most RBDs,
correlations between factor activity levels and clinical bleeding severity
are not strong, it is probably impossible to obtain better threshold levels
than the ones used at the moment. Although these threshold levels to
remain free from bleeding are often used in clinical practice, they should
be interpreted with caution and should not be seen as definite cutoff
levels for an individual patient with a bleeding tendency, which was also
shown by the wide CIs in the original study.4 Caution is especially
warranted concerning patients with FV, FVII, and FXI deficiencies.
The number of RBD patients identified by the RBD BAT was higher
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Figure 4. Correlation and comparison of the ISTH BAT
and RBD BAT. (A) Correlation between ISTH BAT and RBD
BAT scores with linear regression line. (B) Comparison of the
percentage of identified patients (all patients, children youn-
ger than 18 years old, adult women aged 18 years or older,
and adult men aged 18 years or older) by the ISTH BAT and
RBD BAT. *Statistically significant difference.
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identified more men. The RBD BAT corrects for age and sex in the
questionnaire, but the ISTH BAT does not correct for age; it does,
however, correct for sex by using a lower cutoff value for men than
for women. These results suggest that a correction for age in the
RBD BAT helps diagnose RBDs in the pediatric RBD patient
population. The correction for sex seems to be better in the RBD
BAT for women, but there is an underestimation of the RBD BAT in
men. Therefore, the correction factor seems to be inaccurate in the
male patient population. These corrections for sex and age can be
useful for diagnosing other bleeding disorders as well. To conclude
that the RBD BAT is a better diagnostic tool, it will be necessary to
use a healthy control group as a negative control in future studies.
A limitation of this study is the small number of patients per bleeding
disorder, which is inherent in research on rare disorders at
a nationwide level. In the future, it would be beneficial to perform
studies at an international level, which would help enlarge the
patient group. In addition, there may be local differences per HTC in
the diagnosis of RBDs. However, all diagnosed patients were
included to give an overview as complete as possible, and because
all patients were diagnosed in an HTC, they were diagnosed by
experts in the field. Despite the limited number of patients per RBD
in our study population, our study has several significant
implications. For the first time, patients with a fibrinolytic disorder
were included in this type of study, and they had high bleeding
scores. Another of our study’s strong points is that it reports real-life
data. In addition, although most studies include only symptomatic
patients because they have been diagnosed because of a bleeding
phenotype, this study also included known heterozygous family
members as well as patients diagnosed as a result of abnormalities
on coagulation screening before surgery. However, as in all studies of
patients with bleeding disorders, there is still likely to be an
underestimation of the number of asymptomatic patients, because
they are less likely to be diagnosed with a bleeding disorder.
In conclusion, the RBiN study reports real-life data and confirmed
the heterogeneous bleeding tendency of patients with RBDs.
Overall, correlations between baseline factor activity levels and
clinical bleeding severity are poor, which is illustrative of RBDs.
Bleeding was more severe in this patient population than in the
previously described European RBD population. This difference
persisted even when taking into account only patients with rare
coagulation factor deficiencies, because disorders of fibrinolysis
were not included in the previous study. Threshold levels to remain
free from bleeding may not be reliable in this patient population and
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Figure 5. Bleeding grades. (A) Clinical bleeding severity
of patients with an RBD. (B) Patients with more severe
bleeding than expected, taking into account previously
determined baseline factor activity levels.
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